Abstract

The coming decades will see most ailments from chronic metabolic disorders, to monogenic disease, to aging, tackled at the molecular level. The distinction between cure and enhancement will disappear. To date, therapies that alter the genes responsible for disease have been showing success in clinical trials. My goal is to streamline the regulatory approval of gene therapies with early patient access and subsequent data. I founded BioViva in 2015 for the purpose of analyzing medical data from current cutting edge gene therapies done in clinics worldwide by consent. Our researchers analyse the data, and thereby create a positive feedback loop, which then serves to improve innovative therapies. The future looks brilliant.